<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918398</url>
  </required_header>
  <id_info>
    <org_study_id>D9831C00003</org_study_id>
    <secondary_id>EudraCT No. 2009-010964-40</secondary_id>
    <nct_id>NCT00918398</nct_id>
  </id_info>
  <brief_title>AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations</brief_title>
  <official_title>An Open, Single-dose, Phase I, 4-period Partly Crossover Study in Healthy Men or Women to Assess Relative Bioavailability of Oral Administration of AZD1981 Via Tablets Compared With Suspension and Basic Systemic Pharmacokinetic Parameters After Intravenous Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate the pharmacokinetics of AZD1981 given in different
      formulations and to measure renal clearance
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK samples for AZD1981 from both blood and urine</measure>
    <time_frame>Intense PK-sampling during the 24 hours following dose and additional samples up to 60 hours after dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events and laboratory safety lab)</measure>
    <time_frame>Adverese events registered during study and vital signs and ECG at visit 1,2 ,6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Healthy</condition>
  <condition>Postmenopausal</condition>
  <condition>Surgically Sterile Women</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981, 100 mg iv infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981, 514 mg oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981, 500 mg oral tablet A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981, 500 mg oral tablet B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>100 mg iv infusion, single dose, 4 hours infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>514 mg oral solution, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Men or post-menopausal or surgically sterile women, aged 18 to 55 years

          -  Have a body mass index between 19 and 30 kg/m2 and weigh at least 50 kg and no more
             than 100 kg

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to Visit 1
             (pre-entry)

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the result of the study, or the subjectÂ´s ability to participate

          -  Any clinically relevant abnormal findings in phys.examination, clinical chemistry,
             haematology, urinalysis, vital signs, or ECG at baseline which, in the opinion of the
             investigator, may put the subject at risk because of his participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Pettersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Eden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>July 29, 2009</last_update_submitted>
  <last_update_submitted_qc>July 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christer Hultquist, Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Lund, Sweden</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

